Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3823801
Max Phase: Preclinical
Molecular Formula: C11H16N6O3
Molecular Weight: 280.29
Molecule Type: Small molecule
Associated Items:
ID: ALA3823801
Max Phase: Preclinical
Molecular Formula: C11H16N6O3
Molecular Weight: 280.29
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CNc1nc2c(N)ncnc2n1[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Standard InChI: InChI=1S/C11H16N6O3/c1-4-6(18)7(19)10(20-4)17-9-5(16-11(17)13-2)8(12)14-3-15-9/h3-4,6-7,10,18-19H,1-2H3,(H,13,16)(H2,12,14,15)/t4-,6-,7-,10-/m1/s1
Standard InChI Key: ZITVQRKKQVDOKD-KQYNXXCUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 280.29 | Molecular Weight (Monoisotopic): 280.1284 | AlogP: -0.91 | #Rotatable Bonds: 2 |
Polar Surface Area: 131.34 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.48 | CX Basic pKa: 3.49 | CX LogP: -0.89 | CX LogD: -0.89 |
Aromatic Rings: 2 | Heavy Atoms: 20 | QED Weighted: 0.56 | Np Likeness Score: 0.67 |
1. Cheeseman MD, Westwood IM, Barbeau O, Rowlands M, Dobson S, Jones AM, Jeganathan F, Burke R, Kadi N, Workman P, Collins I, van Montfort RL, Jones K.. (2016) Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70., 59 (10): [PMID:27119979] [10.1021/acs.jmedchem.5b02001] |
Source(1):